We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 19, 2020

Antecedent Administration of ACEIs or ARBs and Survival After Hospitalization for SARS-CoV-2

Journal of the American Heart Association


Additional Info

Journal of the American Heart Association
Antecedent Administration of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for SARS-CoV-2 (COVID-19)
J Am Heart Assoc 2020 Oct 07;[EPub Ahead of Print], A Palazzuoli, M Mancone, GM De Ferrari, G Forleo, GG Secco, GM Ruocco, F D'Ascenzo, S Monticone, A Paggi, M Vicenzi, AG Palazzo, M Landolina, E Taravelli, G Tavazzi, F Blasi, F Infusino, F Fedele, FG De Rosa, M Emmett, JM Schussler, KM Tecson, PA McCullough

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading